Highest-materiality recent filing
RevMed Q1 net loss $453.8M, daraxonrasib shows OS 13.2 mo in pancreatic cancer
Daraxonrasib Phase 3 RASolute 302: median OS 13.2 mo vs 6.7 mo chemo (HR 0.40); NDA submission planned.
Revolution Medicines issues $500M 0.50% convertible notes due 2033
Issued $500M 0.50% Convertible Senior Notes due 2033 under indenture with U.S. Bank Trust as trustee.
Revolution Medicines raises ~$2.15B via equity and convertible note offerings
Equity offering: 10,563,381 shares at $142/sh + full over-allotment of 1,584,506 shares; net proceeds ~$1.65B.
Revolution Medicines' daraxonrasib Phase 3 trial meets OS endpoint: 13.2 vs 6.7 months, HR 0.40
Phase 3 RASolute 302 trial: median OS 13.2 mo vs 6.7 mo for chemo (HR 0.40, p<0.0001); PFS also statistically significant.
Revolution Medicines FY2025 net loss $1.1B; daraxonrasib Phase 3 readout on track for H1 2026
Full year 2025 net loss $1.1B vs $600.1M in 2024; Q4 net loss $364.9M vs $194.6M.
Revolution Medicines Q3 net loss $305.2M; advancing daraxonrasib pivotal trials
Net loss $305.2M vs $156.3M YoY; R&D expense $262.5M (+73%), G&A $52.8M (+120%).
Daraxonrasib shows 35% ORR in 2L PDAC, 55% in 1L combo; Phase 3 planned
2L PDAC: ORR 29-35% (RAS G12X and broader mutant), DCR 92-95%, median PFS 8.1-8.5 mo, median OS 13.1-15.6 mo.
Revolution Medicines Q2 net loss $247.8M; advances Phase 3 RAS trials; $2B Royalty Pharma deal
Net loss $247.8M vs $133.2M YoY; R&D expenses rose to $224.1M; FY2025 net loss guidance $1.03B-$1.09B.
Revolution Medicines secures up to $2B financing from Royalty Pharma, withdraws cash runway guidance
Received $250M upfront from Royalty Pharma; up to $1.25B total synthetic royalty on daraxonrasib sales.
Revolution Medicines Q1 net loss $213.4M; highlights encouraging RAS inhibitor data
Net loss $213.4M (vs $116.0M YoY); R&D $205.7M, G&A $35.0M; cash $2.1B.
Revolution Medicines Q4 2024 net loss $194.6M, cash $2.3B; Phase 3 PDAC enrollment target 2025
Q4 net loss $194.6M vs $161.5M YoY; full year net loss $600.1M vs $436.4M.
Offering of 16,576,088 common shares and pre-funded warrants for 2,173,917 shares closed Dec 5, 2024.
RMC-6236 shows 38% ORR in NSCLC, 27-36% in PDAC; median PFS 9.8 mo and 8.5-8.8 mo
NSCLC efficacy: ORR 38% (15/40), median PFS 9.8 mo, median OS 17.7 mo in RAS G12X pts (cutoff Sept 30, 2024).
RevMed Q3 net loss $156M; Phase 3 PDAC trial started, RMC-9805 initial data
Net loss of $156.3M for Q3 2024 vs. $108.4M in Q3 2023; R&D expenses rose to $151.8M.
Revolution Medicines reports RMC-9805 clinical data: 30% ORR in 2L+ PDAC at 1,200 mg/day
RMC-9805 monotherapy showed no Grade 4/5 TRAEs, no discontinuations; 3% dose reduction rate overall (179 patients).
RMC-6236 shows 8.5-month median PFS in 2L metastatic PDAC
Median PFS of 8.5 months (95% CI: 5.3-11.7) in 2L PDAC with KRAS G12X; 4.4 months in 3L+.
Revolution Medicines Q2 net loss $133M; advances RMC-6236 toward Phase 3 in PDAC
Q2 net loss $133.2M vs $98.3M YoY; revenue zero due to Sanofi collaboration termination.
Net loss for FY2024 expected $560-600M, including $70-80M non-cash stock-based comp.
Revolution Medicines Q1 net loss $116M; cash $1.70B; plans pivotal RMC-6236 trials in H2 2024
Net loss of $116.0M for Q1 2024, compared to $68.1M in Q1 2023.
Revolution Medicines reports Q4 net loss $161.5M; cash $1.85B; pipeline on track for pivotal trials
Q4 2023 net loss $161.5M vs $56.5M YoY; full year net loss $436.4M vs $248.7M YoY.
Revolution Medicines issues 54.8M shares for EQRx acquisition; pro forma shows $513M net loss
Acquisition closed Nov 8, 2023; issued 54.8M shares valued at ~$1.086B based on $20.02 RVMD price.
Revolution Medicines completes acquisition of EQRx; exchange ratio 0.1112
Acquisition closed Nov 9, 2023; EQRx stockholders received 0.1112 shares of RVMD common per EQRx share.
Revolution Medicines Q3 net loss $108.4M; updates on RMC-6236, RMC-6291; EQRx close imminent
Q3 2023 net loss $108.4M vs $73.3M; revenue $0 vs $3.4M; R&D spend $107.7M (+55%).
Revolution Medicines sets final merger exchange ratio at 0.1112; ISS/Glass Lewis back deal
Final exchange ratio: 0.1112 RVMD shares per EQRx share, up from illustrative 0.0734.
Revolution Medicines reports Phase 1/1b data for RMC-6236 in NSCLC and PDAC; plans Phase 3 in 2024
RMC-6236 showed ORR 38% (DCR 85%) in evaluable NSCLC (n=40) and ORR 20% (DCR 87%) in PDAC (n=46) as of Oct 12, 2023.
Revolution Medicines reports positive clinical data for RMC-6236 and RMC-6291; selects RMC-5127
RMC-6236 shows acceptable safety in 131 patients; common TRAEs include rash (70%) and GI toxicities, mostly Grade 1-2.
Revolution Medicines Q2 net loss $98.3M; clinical updates for RMC-6236 and RMC-6291
Net loss of $98.3M vs $61.2M YoY; revenue from Sanofi collaboration $3.8M, down from $9.1M.
Merger consideration: $200M fixed (7.69M shares) plus $870M based on pre-meeting VWAP with 6% discount; expected close Nov 2023.
Revolution Medicines Q1 net loss $68.1M, cash $909.8M; guides FY net loss $360-400M
Net loss of $68.1M for Q1 2023 vs $57.6M loss in Q1 2022; R&D expenses $68.9M (up 22% YoY).
Revolution Medicines closes public offering of 15.7M shares for $323.6M net proceeds
Offering of 15,681,818 shares of common stock at $22.00 per share to the public.
Revolution Medicines reports FY2022 net loss $248.7M; cash $644.9M; provides clinical updates
Net loss $248.7M for FY2022 vs $187.1M in 2021; Q4 net loss $56.5M.
Revolution Medicines reports Q3 net loss $73.3M; cash $655M; clinical trials progressing
Net loss of $73.3M for Q3 2022, up from $52.9M in Q3 2021; revenue $3.4M from Sanofi collaboration.
Revolution Medicines Q2 net loss $61.2M; advances first two RAS(ON) inhibitors into clinic
Net loss $61.2M in Q2 2022 vs $44.3M in Q2 2021; revenue from Sanofi collab $9.1M.
Revolution Medicines raises $248M net in public offering of 13.225M shares at $20/share
Sold 13.225M shares (including full exercise of underwriters' option) at $20.00 per share public price.
Revolution Medicines Q1 net loss $57.6M; RAS(ON) inhibitors advancing toward clinic
Net loss $57.6M vs $37.2M YoY; revenue $7.6M from Sanofi collaboration (down from $10.2M).
Revolution Medicines Q4 net loss $52.7M, FY2021 net loss $187.1M; RAS pipeline advances
Cash, cash equivalents and marketable securities $577.1M at Dec 31, 2021 vs $440.7M at Dec 31, 2020.
Dr. Kelsey will transition from his role as the Company’s president, research and development to a new position as senior advisor to the chief executive officer effective as of July 1, 2026.
On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “Company”) of his intent to retire from his employment with the Company effective as of January 4, 2027.
On June 18, 2025, Barbara Weber, M.D., communicated her decision to resign from the board of directors (the “Board”) of Revolution Medicines, Inc.
On August 5, 2024, the board of directors (the “Board”) of the Company increased the authorized size of the Board to ten directors and appointed Frank K. Clyburn, Jr. as a member of the Board.
the Revolution Medicines board of directors (the “Board”) appointed Sandra J. Horning, M.D., as a member of the Board.
On August 31, 2023, Eric T. Schmidt, Ph.D., resigned from the Board of Directors (the “Board”) of Revolution Medicines, Inc. (the “Company”), effective September 5, 2023.
On September 1, 2022, the Board of Directors (the “Board”) of Revolution Medicines, Inc. (the “Company”) promoted Jack Anders, age 45, to serve as the Chief Financial Officer of the Company, effective immediately.
Dr. Kim was appointed to fill the vacancy on the Board created by the resignation of Neil Exter, who resigned from the Board, effective July 12, 2022.
On July 9, 2022, the Board of Directors (“Board”) of Revolution Medicines, Inc. (the “Company”) appointed Lorence Kim, M.D., as a member of the Board, effective July 12, 2022.
Max materiality 0.90 · Median 0.70 · Most common event earnings